T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a single arm open-label multi-center phase II study, investigating disease control
rate after 3 months of treatment with trastuzumab-emtansine/osimertinib combination therapy
in patients with advanced EGFR mutation positive non-small cell lung cancer (NSCLC) with HER2
bypass track resistance.